Amedica announces Pricing of Public Offering to Raise $4.5 Million SALT LAKE CITY, UT - 01/19/17 - Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride ceramics, today announced

announces Pricing of Public Offering to Raise $4.5 Million

LAKE CITY, UT - 01/19/17 - Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon

nitride ceramics, today announced the pricing of an underwritten public offering of common stock and warrants with a public offering

price of $0.51 for one share of common stock and 0.45 warrants. Each whole warrant is exercisable for one share of common stock.

The Company expects to receive gross proceeds of approximately $4.5 million, before deducting underwriting discounts and commissions

and other estimated offering expenses. The Company has also granted a 45-day option to the underwriters to purchase up to an

additional 15% of the shares of common stock plus up to 15% of the warrants; provided that in no event may the aggregate market

value of securities sold in the offering, including from the over-allotment option, exceed the limitations set forth in Rule I.B.6

of Form S-3 solely to cover over-allotments, if any.

warrants have an exercise price of $0.55 per share, are exercisable immediately, and will expire five years from the date of issuance.

offering is expected to close on or about January 24, 2017, subject to customary closing conditions.

Group LLC is acting as sole book-running manager for the offering.

intends to use the net proceeds from the offering to (1) remain in compliance with the financial covenants in its outstanding

Loan and Security Agreement; (2) support working capital needs and other general corporate purposes; (3) fund research and development

and commercialization activities of Amedica's product candidates, including the funding of clinical trials Amedica plans

to conduct for its product candidates; and (4) continue to build sales, marketing and distribution capabilities for Amedica's

silicon nitride technology platform and other products, including the costs of inventory and instruments.

common stock and warrants were offered by means of a preliminary prospectus supplement and accompanying prospectus, which was

filed with the United States Securities and Exchange Commission ("SEC") on January 19, 2017 and forms a part of the

effective registration statement on Form S-3 (File No. 333-205545), which was declared effective by the SEC on July 20, 2015.

A final prospectus relating to this offering will be filed by Amedica with the SEC. Copies of the final prospectus can be obtained,

when available, at the website of the SEC at http://www.sec.gov or from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New

York, NY 10174, at 212-895-3745.

press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be

any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration

or qualification under the securities laws of any such jurisdiction.

is focused on the development and application of interbody implants manufactured with medical-grade silicon nitride ceramic. Amedica

markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip

and knee arthroplasty as well as dental applications. The Company's products are manufactured in its ISO 13485 certified

manufacturing facility and through its partnership with Kyocera, one of the world's largest ceramic manufacturers. Amedica's

FDA-cleared and CE-marked spine products are currently marketed in the U.S. and select markets in Europe and South America through

its distributor network and its growing OEM and private label partnerships.

more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.

press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933

and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. These statements

and similar statements are subject to risks and uncertainties such as changes in the market impacting the ability of the Company

to close the expected offering. Additional factors that could cause actual results to differ materially from those contemplated

within this press release can also be found in Amedica's Risk Factors disclosure in its Annual Report on Form 10-K, filed

with the Securities and Exchange Commission (SEC) on March 23, 2016, and in Amedica's other filings with the SEC. Amedica

disclaims any obligation to update any forward-looking statements.